Penumbra to be Acquired by Boston Scientific for $15 Billion, Offering Significant Premium

summarizeSummary

Penumbra Inc. has agreed to be acquired by Boston Scientific Corporation for $15 billion in cash and stock, representing a substantial premium for shareholders and marking a transformative event for the company.

check_boxKey Events

• Acquisition Agreement

  Boston Scientific Corporation will acquire Penumbra Inc. for a total consideration of $15 billion, or $374 per Penumbra common share, funded by approximately $11 billion in cash and $4 billion in Boston Scientific stock.

• Significant Premium for Shareholders

  The acquisition price of $374 per share represents a notable premium over Penumbra's current stock price of $354.66 and its 52-week high of $355.47, providing substantial value to shareholders.

• Strategic Market Expansion

  The acquisition allows Boston Scientific to enter high-growth segments such as mechanical thrombectomy and neurovascular, leveraging Penumbra's differentiated portfolio.

• Leadership Continuity and Integration

  Penumbra's Chairman and CEO, Adam Elsesser, will join Boston Scientific's Board of Directors and plans to elect to receive Boston Scientific stock for his Penumbra shares, signaling confidence in the combined entity. Penumbra is expected to operate largely as a standalone organization within Boston Scientific.

auto_awesomeAnalysis

This acquisition is a highly significant event for Penumbra, as it will cease to be an independent public company. The $15 billion valuation, which is above the company's current market capitalization and 52-week high, provides a substantial return for shareholders. The deal is expected to close in 2026 and will integrate Penumbra's high-growth neurovascular and mechanical thrombectomy segments into Boston Scientific's portfolio, while Penumbra will largely operate as a standalone entity. Penumbra's CEO joining Boston Scientific's board and electing to receive stock signals confidence in the combined future.